Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Companion Test Approval Clears Path For Further R&D Alliances

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncologic drug/diagnostic markers show further room for co-development, as demonstrated by the pairing of the colorectal cancer drug Erbitux and DakoCytomation's EGFR pharmDx. ImClone drug reimbursement trends likely will drive uptake of the diagnostic.

You may also be interested in...



Erbitux Phase IV Studies Will Evaluate EGFR Expression As Patient Selection Criterion

Two of 13 total postmarketing commitments involve studying the efficacy of Erbitux in patients with EGFR-negative colorectal cancer. Other Phase IVs include a dose finding study in the pediatric population.

Medtronic, Genzyme Team Up To Develop Cellular Cardiac Therapy

Genzyme expects to complete enrollment of its Phase II myoblast cardiac therapy trial by late 2006. While the clinical trials are ongoing, the company will outfit Medtronic’s TransAccess catheter for myoblast delivery. CBER likely would review the combination product.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel